My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

45.96 +0.19 (+0.42%)

Streaming Delayed Price Updated: 11:29 AM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus ↗

July 09, 2025

While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.

Via Stocktwits

Topics ETFs Government Stocks

Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst ↗

July 08, 2025

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.

Via Benzinga

Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗

July 07, 2025

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.

Via Investor's Business Daily

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

July 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma ↗

July 03, 2025

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 30, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 28, 2025

From Pomerantz LLP

Via GlobeNewswire

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

June 28, 2025

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

Via MarketBeat

Why This Biotech Stock Just Doubled In A Single Day ↗

June 26, 2025

Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 26, 2025

Via ACCESS Newswire

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? ↗

June 25, 2025

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 25, 2025

Via ACCESS Newswire

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗

June 25, 2025

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 24, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Why Is Cidara Therapeutics Stock Trading Higher On Monday? ↗

June 23, 2025

Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.

Via Benzinga

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder ↗

June 20, 2025

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.

Via Benzinga

Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull ↗

June 20, 2025

The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.

Via Stocktwits

Topics Supply Chain

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 20, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm

June 16, 2025

From The Schall Law Firm

Via Business Wire

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

June 15, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 15, 2025

From Pomerantz LLP

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)

June 13, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

June 12, 2025

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

Via MarketBeat

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial ↗

June 11, 2025

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 10, 2025

From Pomerantz LLP

Via GlobeNewswire

American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance ↗

June 10, 2025

The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.